Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
Approved for people with type 1 diabetes ages 2 and up.
Approved for people with diabetes mellitus, ages 14 and up.
For people who take multiple daily injections.
For people 14 to 75 years of age with diabetes mellitus.
This course includes the science leading to the Medtronic Extended infusion set, key training concepts, and a quick reference prescription guide.
Compare available infusion sets
An online learning experience for healthcare professionals.
Sign up for free interactive webinars or watch on-demand videos.
Training references, quick reference guides, and other PDFs.
Helping patients take action to preempt hypoglycemia and help maximize Time in Range.
Up-to 60-minute high and low predictions may allow patients enough time to act.
Martín-Timón, Cañizo-Gómez. Diabetes. 2015;6(7):912.
Gehlaut, Richa R., et al. J Diab Science Tech. 2015;9(5):999-1005.
Guardian™ Connect SSED, page 19, Table 5. 98.5% Glucose Correct Detection Rate based on Predictive Alerts at 30 minutes when worn on the abdomen; Data includes all US patients uploading voluntarily to CareLink™ Personal software from June 2018 to Feb 2019 N=802. Patients included might be on other diabetes therapy, including insulin pumps, multiple daily injections or oral medications.
Arunachalam S, et al. Poster presented at ADA 2019. 79th Scientific Sessions. June 7th-11th. San Francisco, California. #939-P; Data includes all US patients uploading voluntarily to CareLink™ Personal Software from June 2018 to Feb 2019 N=802. Patients included might be on other diabetes therapy, including insulin pumps, multiple daily injections or oral medications.
Aanstoot H-J, Rodriguez H, Weinzimer S, Vint N, Koeneman L. Precision Dosing of Rapid-Acting Insulin Matters. Diabetes Technology & Therapeutics, 2020;22(5).
Zaugg, S.D., et al. Diabetes numeracy and blood glucose control: association with type of diabetes and source of care. Clinical diabetes: a publication of the American Diabetes Association 32.4 (2014): 152-157.
Anderson DG. Multiple daily injections in young patients using the ezy-BICC bolus insulin calculation card, compared to mixed insulin and CSII. Pediatric Diabetes. 2009; 10(5):304-309.
Aronson, R., Reznik, Y., Conget, I., Castañeda, J.A., Runzis, S., Lee, S.W., Cohen, O. and (2016), Sustained efficacy of insulin pump therapy compared with multiple daily injections in type 2 diabetes: 12-month data from the OpT2mise randomized trial. Diabetes Obes Metab, 18: 500-507. https://doi.org/10.1111/dom.12642
Everyone’s experience with diabetes is different. We are committed to providing you with the level of support to help your patients reach their diabetes goals.
In-person or online trainings help patients get started on the right foot and make sure they have everything they need to be successful on a new therapy.
Round-the-clock support for troubleshooting and product assistance.
For more information on individual products, we have a range of resources available online to help.
Diabetes.shop is the place for patients to manage all your supply orders and communication preferences.
For patients who experience chronic pain due to DPN and have not been satisfied by the levels of relief provided by oral pain medication, injections, or other treatments for pain, SCS can provide a new approach for patients looking for solutions.
We are pleased to share that starting on October 1, 2022, Medi-Cal will cover Medtronic continuous glucose monitoring (CGM) systems under the State’s pharmacy benefit program, Medi-Cal Rx. This change means that generally patients will have full coverage under the pharmacy benefit with no out-of-pocket costs for them. The coverage will include the following products:
Important Safety Information: MiniMed™ 770G System with SmartGuard™ Technology
The MiniMed™ 770G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of type 1 diabetes mellitus in persons two years of age and older requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed™ 770G system includes SmartGuard™ technology, which can be programmed to automatically adjust delivery of basal insulin based on continuous glucose monitoring (CGM) sensor glucose (SG) values and can suspend delivery of insulin when the SG value falls below or is predicted to fall below predefined threshold values.
The Medtronic MiniMed™ 770G system consists of the following devices: MiniMed™ 770G insulin pump, the Guardian™ Link (3) transmitter, the Guardian™ Sensor (3), one-press serter, the Accu-Chek® Guide Link blood glucose meter, and the Accu-Chek® Guide test strips. The system requires a prescription.
The Guardian™ Sensor (3) has not been evaluated and is not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required. All therapy adjustments should be based on measurements obtained using a blood glucose meter and not on values provided by the Guardian™ Sensor (3).
All therapy adjustments should be based on measurements obtained using the Accu-Chek® Guide Link blood glucose meter and not on values provided by the Guardian™ Sensor (3). Always check the pump display to ensure the glucose result shown agrees with the glucose results shown on the Accu-Chek® Guide Link blood glucose meter. Do not calibrate your CGM device or calculate a bolus using a blood glucose meter result taken from an alternative site. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise.
WARNING: Do not use the SmartGuard™ Auto Mode for people who require less than 8 units or more than 250 units of total daily insulin per day. A total daily dose of at least 8 units, but no more than 250 units, is required to operate in SmartGuard™ Auto Mode.
WARNING: Do not use the MiniMed™ 770G system until appropriate training has been received from a healthcare professional. Training is essential to ensure the safe use of the MiniMed™ 770G system.
Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. The safety of the MiniMed™ 770G system has not been studied in pregnant women. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult https://www.medtronicdiabetes.com/important-safety-information#minimed-770g and the appropriate user guide at https://www.medtronicdiabetes.com/download-library
Important Safety Information: MiniMed™ 630G System with SmartGuard™ technology
Indicated for the continuous delivery of insulin, at set and variable rates, for the management of diabetes mellitus. MiniMed™ 630G system is approved for ages 14 years or older with Guardian™ Sensor 3 and MiniMed™ 630G system is approved for ages 16 years or older with Enlite™ sensor. Both systems require a prescription. Insulin infusion pumps and associated components of insulin infusion systems are limited to sale by or on the order of a physician and should only be used under the direction of a healthcare professional familiar with the risks of insulin pump therapy. Pump therapy is not recommended for people who are unwilling or unable to perform a minimum of four blood glucose tests per day. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Insulin pumps use rapid-acting insulin. If your insulin delivery is interrupted for any reason, you must be prepared to replace the missed insulin immediately. Replace the infusion set every 48–72 hours, or more frequently per your healthcare professional’s instructions. Insertion of a glucose sensor may cause bleeding or irritation at the insertion site. Consult a physician immediately if you experience significant pain or if you suspect that the site is infected. The information provided by CGM systems is intended to supplement, not replace, blood glucose information obtained using a blood glucose meter. A confirmatory fingerstick using a CONTOUR®NEXT LINK 2.4 meter is required prior to making adjustments to diabetes therapy. Always check the pump display when using a CONTOUR®NEXT LINK 2.4 meter, to ensure the glucose result shown agrees with the glucose results shown on the meter. Do not calibrate your CGM device or calculate a bolus using a result taken from an Alternative Site (palm) or a result from a control solution test. If a control solution test is out of range, please note that the result may be transmitted to your pump when in the “Always” send mode. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise. The MiniMed™ 630G or MiniMed™ 530G system are not intended to be used directly for preventing or treating hypoglycemia but to suspend insulin delivery when the user is unable to respond to the Suspend on low alarm and take measures to prevent or treat hypoglycemia themselves. Therapy to prevent or treat hypoglycemia should be administered according to the recommendations of the user’s healthcare provider.
WARNING: The SmartGuard™ Suspend on low feature will cause the pump to temporarily suspend insulin delivery for two hours when the sensor glucose reaches a set threshold. Under some conditions of use the pump can suspend again, resulting in very limited insulin delivery. Prolonged suspension can increase the risk of serious hyperglycemia, ketosis, and ketoacidosis. Before using the SmartGuard feature, it is important to read the SmartGuard™ feature information in the User Guide and discuss proper use of the feature with your healthcare provider.
See www.medtronicdiabetes.com/importantsafetyinformation and the appropriate user guides for additional important details.
Important Safety Information: Guardian™ Connect CGM System
The Guardian™ Connect system requires a prescription and is indicated for continuous or periodic monitoring of glucose levels in the interstitial fluid under the skin, in patients (14 to 75 years of age) with diabetes mellitus. The system is intended to complement, not replace, information obtained from standard blood glucose monitoring devices, and is not recommended for people who are unwilling or unable to perform a minimum of two meter blood glucose tests per day, or for people who are unable or unwilling to maintain contact with their healthcare professional. The system requires a functioning mobile electronic device with correct settings. If the mobile device is not set up or used correctly, you may not receive sensor glucose information or alerts. For complete details of the system and its components, including warnings, contraindications, and precautions, please consult the user guide at https://www.medtronicdiabetes.com/download-library and important safety information.
Important Safety Information: InPen™ Smart Insulin Pen
The InPen™ requires a prescription. It is a home-use reusable pen injector for single-patient use by people with diabetes under the supervision of an adult caregiver, or by a patient age 7 and older for the self-injection of a desired dose of insulin. The pen injector is compatible with Lilly Humalog® U-100 3.0 mL cartridges, Novo Nordisk Novolog® U-100 3.0 mL cartridges, and Novo Nordisk Fiasp® U-100 3.0 mL cartridges and single-use detachable and disposable pen needles (not included). The pen injector allows the user to dial the desired dose from 0.5 to 30 units in one-half (1/2) unit increments.
The InPen™ dose calculator, a component of the InPen™ app, is indicated for the management of diabetes by people with diabetes under the supervision of an adult caregiver, or by a patient age 7 and older for calculating an insulin dose or carbohydrate intake based on user entered data.
For an insulin dose based on amount of carbohydrates, a healthcare professional must provide patient-speciﬁc target blood glucose, insulin-to-carbohydrate ratio, insulin sensitivity parameters, and duration of insulin action to be programmed into the software prior to use as it is required for set up.
For an insulin dose based on ﬁxed/variable meal sizes, a healthcare professional must provide patient-speciﬁc ﬁxed doses/meal sizes to be programmed into the software prior to use.
For additional product and important safety considerations, see User Guide and http://bit.ly/InPenSafety.
Important Safety Information: i-Port Advance™ Injection Port
i-Port Advance™ injection port is prescription-indicated for patients who administer, or to whom is administered, multiple daily subcutaneous injections of physician prescribed medications, including insulin. The device may remain in place for up to 72 hours to accommodate multiple drug injections without the discomfort of additional needle sticks. Site infection and/or irritation is a risk. Patients experiencing such symptoms should immediately consult their healthcare provider and/ or discontinue use. For complete details, please consult i-Port Advance™ product user guide.